Cinacalcet's effect on the pharmacokinetics of tacrolimus, cyclosporine and mycophenolate in renal transplant recipients

Nephrology Dialysis Transplantation

Volumn 23, Issue 3, 2008, Pages 1048-1053

  Falck, Pål ^a   Vethe, Nils Tore ^b   Åsberg, Anders ^a   Midtvedt, Karsten ^b   Bergan, Stein ^b   Reubsaet, Jan Leo Egge ^a   Holdaas, Hallvard ^b  

^a UNIVERSITY OF OSLO   (Norway)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

Cinacalcet; Cyclosporine; Interaction; Renal function; Renal transplantation; Tacrolimus

Indexed keywords

AM 19; AZATHIOPRINE; CINACALCET; CYCLOSPORIN A; CYCLOSPORIN DERIVATIVE; DRUG METABOLITE; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; STEROID; TACROLIMUS; CYCLOSPORIN; DRUG DERIVATIVE; IMMUNOSUPPRESSIVE AGENT; NAPHTHALENE DERIVATIVE;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG HALF LIFE; FEMALE; HUMAN; HYPERCALCEMIA; HYPERPARATHYROIDISM; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; MALE; PATIENT MONITORING; PRIORITY JOURNAL; SIDE EFFECT; BLOOD; CLINICAL TRIAL; DOSE RESPONSE; KIDNEY; METABOLISM; MIDDLE AGED; PHYSIOLOGY;

ADULT; AGED; CYCLOSPORINE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; NAPHTHALENES; TACROLIMUS;

EID: 42449085455     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfm632     Document Type: Article

References (38)

1. Bonarek H, Merville P, Bonarek M et al. Reduced parathyroid functional mass after successful kidney transplantation. Kidney Int 1999; 56: 642-649
2. Torres A, Rodriguez AP, Concepcion MT et al. Parathyroid function in long-term renal transplant patients: importance of pre-transplant PTH concentrations. Nephrol Dial Transplant 1998; 13: 94-97
3. Torres A, Lorenzo V, Salido E. Calcium metabolism and skeletal problems after transplantation. J Am Soc Nephrol 2002; 13: 551-558
4. Carlini RG, Rojas E, Weisinger JR et al. Bone disease in patients with long-term renal transplantation and normal renal function. Am J Kidney Dis 2000; 36: 160-166
5. Cayco AV, Wysolmerski J, Simpson C et al. Posttransplant bone disease: evidence for a high bone resorption state. Transplantation 2000; 70: 1722-1728
6. Messa P, Sindici C, Cannella G et al. Persistent secondary hyperparathyroidism after renal transplantation. Kidney Int 1998; 54: 1704-1713
7. Leca N, Laftavi M, Gundroo A et al. Early and severe hyperparathyroidism associated with hypercalcemia after renal transplant treated with cinacalcet. Am J Transplant 2006; 6: 2391-2395
8. Kruse AE, Eisenberger U, Frey FJ et al. The calcimimetic cinacalcet normalizes serum calcium in renal transplant patients with persistent hyperparathyroidism. Nephrol Dial Transplant 2005; 20: 1311-1314
9. Serra AL, Schwarz AA, Wick FH et al. Successful treatment of hypercalcemia with cinacalcet in renal transplant recipients with persistent hyperparathyroidism. Nephrol Dial Transplant 2005; 20: 1315-1319
10. Sattler M, Guengerich FP, Yun CH et al. Cytochrome P-450 3A enzymes are responsible for biotransformation of FK506 and rapamycin in man and rat. Drug Metab Dispos 1992; 20: 753-761
11. Christians U, Sewing KF. Cyclosporin metabolism in transplant patients. Pharmacol Ther 1993; 57: 291-345
12. Kumar GN, Sproul C, Poppe L et al. Metabolism and disposition of calcimimetic agent cinacalcet HCl in humans and animal models. Drug Metab Dispos 2004; 32: 1491-1500
13. Asberg A, Christensen H, Hartmann A et al. Pharmacokinetic interactions between microemulsion formulated cyclosporine A and diltiazem in renal transplant recipients. Eur J Clin Pharmacol 1999; 55: 383-387
14. Jensen C, Jordan M, Shapiro R et al. Interaction between tacrolimus and erythromycin. Lancet 1994; 344: 825
15. Shapiro R, Venkataramanan R, Warty VS et al. FK 506 interaction with danazol. Lancet 1993; 341: 1344-1345
16. Hermann M, Asberg A, Reubsaet JL et al. Intake of grapefruit juice alters the metabolic pattern of cyclosporin A in renal transplant recipients. Int J Clin Pharmacol Ther 2002; 40: 451-456
17. Szwarc I, Argiles A, Garrigue V et al. Cinacalcet chloride is efficient and safe in renal transplant recipients with post-transplant hyperparathyroidism. Transplantation 2006; 82: 675-680
18. Perner F. Cyclosporine microemulsion (neoral) absorption profiling and sparse-sample predictors during the first 3 months after renal transplantation. Am J Transplant 2002; 2: 148-56
19. Mahalati K, Belitsky P, Sketris I et al. Neoral monitoring by simplified sparse sampling area under the concentration-time curve: its relationship to acute rejection and cyclosporine nephrotoxicity early after kidney transplantation. Transplantation 1999; 68: 55-62
20. Thervet E, Pfeffer P, Scolari MP et al. Clinical outcomes during the first three months post-transplant in renal allograft recipients managed by C2 monitoring of cyclosporine microemulsion. Transplantation 2003; 76: 903-908
21. Izzedine H, Launay-Vacher V, Karie S et al. Immunosuppressive and calcimimetic drug-drug interactions. Kidney Int 2005; 68: 1903-1904
22. Falck P, Guldseth H, Asberg A et al. Determination of ciclosporin A and its six main metabolites in isolated T-lymphocytes and whole blood using liquid chromatography-tandem mass spectrometry. J Chromatogr B 2007; 852: 345-352
23. FDA. Guidance for Industry: Bioanalytical Method Validation, 2005.
24. Svensson J, Brattstrom C, Sawe J. A simple HPLC method for simultaneous determination of mycophenolic acid and mycophenolic acid glucuronide in plasma. Ther Drug Monit 1999; 21: 322-324
25. Katz DA, Grimm DR, Cassar SC et al. CYP3A5 genotype has a dose-dependent effect on ABT-773 plasma levels. Clin Pharmacol Ther 2004; 75: 516-528
26. Cascorbi I, Gerloff T, Johne A et al. Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects. Clin Pharmacol Ther 2001; 69: 169-174 [erratum: Clin Pharmacol Ther 2004; 75: 124]
27. van Schaik RH, Van Der Heiden IP, Van Den Anker JN et al. CYP3A5 variant allele frequencies in Dutch Caucasians. Clin Chem 2002; 48: 1668-1671
28. Nankivell BJ, Gruenewald SM, Allen RD et al. Predicting glomerular filtration rate after kidney transplantation. Transplantation 1995; 59: 1683-1689
29. EMEA. Note for guidance on the investigation of bioavailability and bioequivalence, 2001.
30. Wong K, Shek C, Chau K et al. Abbreviated tacrolimus area-under-the-curve monitoring for renal transplant recipients. Am J Kidney Dis 2000; 35: 660-666
31. Pisitkun T, Eiam-Ong S, Chusil S et al. The roles of C4 and AUC0-4 in monitoring of tacrolimus in stable kidney transplant patients. Transplant Proc 2002; 34: 3173-3175
32. Harris RZ, Salfi M, Sullivan JT et al. Pharmacokinetics of cinacalcet hydrochloride when administered with ketoconazole. Clin Pharmacokinet 2007; 46: 495-501
33. Kempkes-Koch M, Fobker M, Erren M et al. Cyclosporine A metabolite AM19 as a potential biomarker in urine for CSA nephropathy. Transplant Proc 2001; 33: 2167-2169
34. Christians U, Kohlhaw K, Budniak J et al. Ciclosporin metabolite pattern in blood and urine of liver graft recipients: I. Association of ciclosporin metabolites with nephrotoxicity. Eur J Clin Pharmacol 1991; 41: 285-290
35. El-Amm JM, Doshi MD, Singh A et al. Preliminary experience with cinacalcet use in persistent secondary hyperparathyroidism after kidney transplantation. Transplantation 2007; 83: 546-549
36. Tsuchiya N, Satoh S, Tada H et al. Influence of CYP3A5 and MDR1 (ABCB1) polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients. Transplantation 2004; 78: 1182-1187
37. Haufroid V, Mourad M, Van Kerckhove V et al. The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients. Pharmacogenetics 2004; 14: 147-154
38. Evans WE, McLeod HL. Pharmacogenomics - drug disposition, drug targets, and side effects. N Engl J Med 2003; 348: 538-549